Astemizole inhibits mTOR signaling and angiogenesis by blocking cholesterol trafficking

Junfang Lyu, Eun Ju Yang, Sarah A. Head, Nana Ai, Baoyuan Zhang, Changjie Wu, Ruo Jing Li, Yifan Liu, Harapriya Chakravarty, Shaolin Zhang, Kin Yip Tam, Yongjun Dang, Ho Jeong Kwon, Wei Ge, Jun Liu, Joong Sup Shim

Research output: Contribution to journalArticle

Abstract

Cholesterol plays a key role in membrane protein function and signaling in endothelial cells. Thus, disturbing cholesterol trafficking is an effective approach for inhibiting angiogenesis. We recently identified astemizole (AST), an antihistamine drug, as a cholesterol trafficking inhibitor from a phenotypic screen. In this study, we found that AST induced cholesterol accumulation in the lysosome by binding to the sterol-sensing domain of Niemann-Pick disease, type C1 (NPC1), a lysosomal surface protein responsible for cholesterol transport. Inhibition of cholesterol trafficking by AST led to the depletion of membrane cholesterol, causing SREBP1 nuclear localization. The depletion of membrane cholesterol resulted in dissociation of mammalian target of rapamycin (mTOR) from the lysosomal surface and inactivation of mTOR signaling. These effects were effectively rescued by addition of exogenous cholesterol. AST inhibited endothelial cell proliferation, migration and tube formation in a cholesterol-dependent manner. Furthermore, AST inhibited zebrafish angiogenesis in a cholesterol-dependent manner. Together, our data suggest that AST is a new class of NPC1 antagonist that inhibits cholesterol trafficking in endothelial cells and angiogenesis.

Original languageEnglish (US)
Pages (from-to)1175-1185
Number of pages11
JournalInternational Journal of Biological Sciences
Volume14
Issue number10
DOIs
StatePublished - Jun 23 2018

Fingerprint

Astemizole
trafficking
Sirolimus
angiogenesis
Cholesterol
cholesterol
membrane
protein
sterol
Type C Niemann-Pick Disease
endothelial cells
inhibitor
Endothelial Cells
drug
Membrane Proteins
Anticholesteremic Agents
antihistamines
Membranes
Histamine Antagonists
Zebrafish

Keywords

  • Angiogenesis
  • Astemizole
  • Cholesterol trafficking
  • mTOR
  • NPC1

ASJC Scopus subject areas

  • Ecology, Evolution, Behavior and Systematics
  • Applied Microbiology and Biotechnology
  • Molecular Biology
  • Developmental Biology
  • Cell Biology

Cite this

Astemizole inhibits mTOR signaling and angiogenesis by blocking cholesterol trafficking. / Lyu, Junfang; Yang, Eun Ju; Head, Sarah A.; Ai, Nana; Zhang, Baoyuan; Wu, Changjie; Li, Ruo Jing; Liu, Yifan; Chakravarty, Harapriya; Zhang, Shaolin; Tam, Kin Yip; Dang, Yongjun; Kwon, Ho Jeong; Ge, Wei; Liu, Jun; Shim, Joong Sup.

In: International Journal of Biological Sciences, Vol. 14, No. 10, 23.06.2018, p. 1175-1185.

Research output: Contribution to journalArticle

Lyu, J, Yang, EJ, Head, SA, Ai, N, Zhang, B, Wu, C, Li, RJ, Liu, Y, Chakravarty, H, Zhang, S, Tam, KY, Dang, Y, Kwon, HJ, Ge, W, Liu, J & Shim, JS 2018, 'Astemizole inhibits mTOR signaling and angiogenesis by blocking cholesterol trafficking', International Journal of Biological Sciences, vol. 14, no. 10, pp. 1175-1185. https://doi.org/10.7150/ijbs.26011
Lyu, Junfang ; Yang, Eun Ju ; Head, Sarah A. ; Ai, Nana ; Zhang, Baoyuan ; Wu, Changjie ; Li, Ruo Jing ; Liu, Yifan ; Chakravarty, Harapriya ; Zhang, Shaolin ; Tam, Kin Yip ; Dang, Yongjun ; Kwon, Ho Jeong ; Ge, Wei ; Liu, Jun ; Shim, Joong Sup. / Astemizole inhibits mTOR signaling and angiogenesis by blocking cholesterol trafficking. In: International Journal of Biological Sciences. 2018 ; Vol. 14, No. 10. pp. 1175-1185.
@article{6056c9b0e9ee41b994a9a7669454d235,
title = "Astemizole inhibits mTOR signaling and angiogenesis by blocking cholesterol trafficking",
abstract = "Cholesterol plays a key role in membrane protein function and signaling in endothelial cells. Thus, disturbing cholesterol trafficking is an effective approach for inhibiting angiogenesis. We recently identified astemizole (AST), an antihistamine drug, as a cholesterol trafficking inhibitor from a phenotypic screen. In this study, we found that AST induced cholesterol accumulation in the lysosome by binding to the sterol-sensing domain of Niemann-Pick disease, type C1 (NPC1), a lysosomal surface protein responsible for cholesterol transport. Inhibition of cholesterol trafficking by AST led to the depletion of membrane cholesterol, causing SREBP1 nuclear localization. The depletion of membrane cholesterol resulted in dissociation of mammalian target of rapamycin (mTOR) from the lysosomal surface and inactivation of mTOR signaling. These effects were effectively rescued by addition of exogenous cholesterol. AST inhibited endothelial cell proliferation, migration and tube formation in a cholesterol-dependent manner. Furthermore, AST inhibited zebrafish angiogenesis in a cholesterol-dependent manner. Together, our data suggest that AST is a new class of NPC1 antagonist that inhibits cholesterol trafficking in endothelial cells and angiogenesis.",
keywords = "Angiogenesis, Astemizole, Cholesterol trafficking, mTOR, NPC1",
author = "Junfang Lyu and Yang, {Eun Ju} and Head, {Sarah A.} and Nana Ai and Baoyuan Zhang and Changjie Wu and Li, {Ruo Jing} and Yifan Liu and Harapriya Chakravarty and Shaolin Zhang and Tam, {Kin Yip} and Yongjun Dang and Kwon, {Ho Jeong} and Wei Ge and Jun Liu and Shim, {Joong Sup}",
year = "2018",
month = "6",
day = "23",
doi = "10.7150/ijbs.26011",
language = "English (US)",
volume = "14",
pages = "1175--1185",
journal = "International Journal of Biological Sciences",
issn = "1449-2288",
publisher = "Ivyspring International Publisher",
number = "10",

}

TY - JOUR

T1 - Astemizole inhibits mTOR signaling and angiogenesis by blocking cholesterol trafficking

AU - Lyu, Junfang

AU - Yang, Eun Ju

AU - Head, Sarah A.

AU - Ai, Nana

AU - Zhang, Baoyuan

AU - Wu, Changjie

AU - Li, Ruo Jing

AU - Liu, Yifan

AU - Chakravarty, Harapriya

AU - Zhang, Shaolin

AU - Tam, Kin Yip

AU - Dang, Yongjun

AU - Kwon, Ho Jeong

AU - Ge, Wei

AU - Liu, Jun

AU - Shim, Joong Sup

PY - 2018/6/23

Y1 - 2018/6/23

N2 - Cholesterol plays a key role in membrane protein function and signaling in endothelial cells. Thus, disturbing cholesterol trafficking is an effective approach for inhibiting angiogenesis. We recently identified astemizole (AST), an antihistamine drug, as a cholesterol trafficking inhibitor from a phenotypic screen. In this study, we found that AST induced cholesterol accumulation in the lysosome by binding to the sterol-sensing domain of Niemann-Pick disease, type C1 (NPC1), a lysosomal surface protein responsible for cholesterol transport. Inhibition of cholesterol trafficking by AST led to the depletion of membrane cholesterol, causing SREBP1 nuclear localization. The depletion of membrane cholesterol resulted in dissociation of mammalian target of rapamycin (mTOR) from the lysosomal surface and inactivation of mTOR signaling. These effects were effectively rescued by addition of exogenous cholesterol. AST inhibited endothelial cell proliferation, migration and tube formation in a cholesterol-dependent manner. Furthermore, AST inhibited zebrafish angiogenesis in a cholesterol-dependent manner. Together, our data suggest that AST is a new class of NPC1 antagonist that inhibits cholesterol trafficking in endothelial cells and angiogenesis.

AB - Cholesterol plays a key role in membrane protein function and signaling in endothelial cells. Thus, disturbing cholesterol trafficking is an effective approach for inhibiting angiogenesis. We recently identified astemizole (AST), an antihistamine drug, as a cholesterol trafficking inhibitor from a phenotypic screen. In this study, we found that AST induced cholesterol accumulation in the lysosome by binding to the sterol-sensing domain of Niemann-Pick disease, type C1 (NPC1), a lysosomal surface protein responsible for cholesterol transport. Inhibition of cholesterol trafficking by AST led to the depletion of membrane cholesterol, causing SREBP1 nuclear localization. The depletion of membrane cholesterol resulted in dissociation of mammalian target of rapamycin (mTOR) from the lysosomal surface and inactivation of mTOR signaling. These effects were effectively rescued by addition of exogenous cholesterol. AST inhibited endothelial cell proliferation, migration and tube formation in a cholesterol-dependent manner. Furthermore, AST inhibited zebrafish angiogenesis in a cholesterol-dependent manner. Together, our data suggest that AST is a new class of NPC1 antagonist that inhibits cholesterol trafficking in endothelial cells and angiogenesis.

KW - Angiogenesis

KW - Astemizole

KW - Cholesterol trafficking

KW - mTOR

KW - NPC1

UR - http://www.scopus.com/inward/record.url?scp=85052985913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052985913&partnerID=8YFLogxK

U2 - 10.7150/ijbs.26011

DO - 10.7150/ijbs.26011

M3 - Article

C2 - 30123067

AN - SCOPUS:85052985913

VL - 14

SP - 1175

EP - 1185

JO - International Journal of Biological Sciences

JF - International Journal of Biological Sciences

SN - 1449-2288

IS - 10

ER -